It is definitely a strong contender.

You might be surprised that I've put COVID-19 first on this list. Pfizer's sinking revenue, profits, and share price over the last few years have been primarily caused by the steep sales decline for ...

Pfizer draws attention as healthcare steadies a mixed market, supported by oncology progress, vaccine development and ...

Pfizers approaching patent cliff and expanding pipeline remain central as the pharmaceutical group advances oncology programs ...

Pfizer reported third-quarter revenue and adjusted profit that blew past expectations. The company hiked its full-year outlook as its Covid vaccine and antiviral pill Paxlovid helped boost sales. It ...

Pfizer reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook as the drugmaker works to slash costs. The results come as Pfizer scrambles to ...